_id
690dae7cccc777a4e85d0a90
Ticker
AMPH
Name
Amphastar P
Exchange
NASDAQ
Address
11570 6th Street, Rancho Cucamonga, CA, United States, 91730
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.amphastar.com
Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Last Close
25.71
Volume
410857
Current Price
25.9
Change
0.7390120575651409
Last Updated
2025-11-28T12:12:23.245Z
Image
-
Ipo Date
2014-06-25T00:00:00.000Z
Market Cap
1272105472
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9240076923076924
Sentiment Sources
13
Rating
3.6667
Target Price
32
Strong Buy
2
Buy
0
Hold
4
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
191840000
Cost Of Revenue
93194000
Gross Profit
98646000
Operating Expenses
73326000
Operating Income
25320000
Interest Expense
6284000
Pretax Income
21513000
Net Income
17350000
Eps
0.36390712502883993
Dividends Per Share
-
Shares Outstanding
45952174
Income Tax Expense
4163000
EBITDA
41926000
Operating Margin
13.198498748957466
Total Other Income Expense Net
-3807000
Cash
216500000
Short Term Investments
62144000
Receivables
146808000
Inventories
185932000
Total Current Assets
639470000
Property Plant Equipment
353525000
Total Assets
1666222000
Payables
40540000
Short Term Debt
8750000
Long Term Debt
608582000
Total Liabilities
889476000
Equity
776746000
Depreciation
14129000
Change In Working Capital
11997000
Cash From Operations
52583000
Capital Expenditures
5348000
Cash From Investing
-19619000
Cash From Financing
-4347000
Net Change In Cash
28576000
PE
12.1062
PB
1.5897530209360589
ROE
2.2336774183581247
ROA
1.0412778129204872
FCF
47235000
Fcf Percent
0.24622080900750626
Piotroski FScore
4
Health Score
62
Deep Value Investing Score
5.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
6.3
Garp Investing Score
3.5
Growth Investing Score
3.5
Momentum Investing Score
6.5
Net Net Investing Score
2.5
Quality Investing Score
5.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
191840000
Quarters > 0 > income Statement > cost Of Revenue
93194000
Quarters > 0 > income Statement > gross Profit
98646000
Quarters > 0 > income Statement > operating Expenses
73326000
Quarters > 0 > income Statement > operating Income
25320000
Quarters > 0 > income Statement > interest Expense
6284000
Quarters > 0 > income Statement > pretax Income
21513000
Quarters > 0 > income Statement > net Income
17350000
Quarters > 0 > income Statement > eps
0.36390712502883993
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
47677000
Quarters > 0 > income Statement > income Tax Expense
4163000
Quarters > 0 > income Statement > EBITDA
41926000
Quarters > 0 > income Statement > operating Margin
13.198498748957466
Quarters > 0 > income Statement > total Other Income Expense Net
-3807000
Quarters > 0 > balance Sheet > cash
216500000
Quarters > 0 > balance Sheet > short Term Investments
62144000
Quarters > 0 > balance Sheet > receivables
146808000
Quarters > 0 > balance Sheet > inventories
185932000
Quarters > 0 > balance Sheet > total Current Assets
639470000
Quarters > 0 > balance Sheet > property Plant Equipment
353525000
Quarters > 0 > balance Sheet > total Assets
1666222000
Quarters > 0 > balance Sheet > payables
40540000
Quarters > 0 > balance Sheet > short Term Debt
8750000
Quarters > 0 > balance Sheet > long Term Debt
608582000
Quarters > 0 > balance Sheet > total Liabilities
889476000
Quarters > 0 > balance Sheet > equity
776746000
Quarters > 0 > cash Flow > net Income
17350000
Quarters > 0 > cash Flow > depreciation
14129000
Quarters > 0 > cash Flow > change In Working Capital
11997000
Quarters > 0 > cash Flow > cash From Operations
52583000
Quarters > 0 > cash Flow > capital Expenditures
5348000
Quarters > 0 > cash Flow > cash From Investing
-19619000
Quarters > 0 > cash Flow > cash From Financing
-4347000
Quarters > 0 > cash Flow > net Change In Cash
28576000
Quarters > 0 > ratios > PE
0.36390712502883993
Quarters > 0 > ratios > PB
1.5897530209360589
Quarters > 0 > ratios > ROE
2.2336774183581247
Quarters > 0 > ratios > ROA
1.0412778129204872
Quarters > 0 > ratios > FCF
47235000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.24622080900750626
Quarters > 0 > health Score
62
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
174414000
Quarters > 1 > income Statement > cost Of Revenue
87924000
Quarters > 1 > income Statement > gross Profit
86490000
Quarters > 1 > income Statement > operating Expenses
44306000
Quarters > 1 > income Statement > operating Income
42184000
Quarters > 1 > income Statement > interest Expense
6281000
Quarters > 1 > income Statement > pretax Income
39335000
Quarters > 1 > income Statement > net Income
31030000
Quarters > 1 > income Statement > eps
0.6447390292553191
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
48128000
Quarters > 1 > income Statement > income Tax Expense
8305000
Quarters > 1 > income Statement > EBITDA
61855000
Quarters > 1 > income Statement > operating Margin
24.1861318472141
Quarters > 1 > income Statement > total Other Income Expense Net
-2849000
Quarters > 1 > balance Sheet > cash
187689000
Quarters > 1 > balance Sheet > short Term Investments
44062000
Quarters > 1 > balance Sheet > receivables
134585000
Quarters > 1 > balance Sheet > inventories
191731000
Quarters > 1 > balance Sheet > total Current Assets
580830000
Quarters > 1 > balance Sheet > property Plant Equipment
354734000
Quarters > 1 > balance Sheet > total Assets
1615333000
Quarters > 1 > balance Sheet > payables
41881000
Quarters > 1 > balance Sheet > short Term Debt
8806000
Quarters > 1 > balance Sheet > long Term Debt
607727000
Quarters > 1 > balance Sheet > total Liabilities
857851000
Quarters > 1 > balance Sheet > equity
757482000
Quarters > 1 > cash Flow > net Income
31030000
Quarters > 1 > cash Flow > depreciation
13018000
Quarters > 1 > cash Flow > change In Working Capital
-18525000
Quarters > 1 > cash Flow > cash From Operations
35592000
Quarters > 1 > cash Flow > capital Expenditures
10565000
Quarters > 1 > cash Flow > cash From Investing
-625000
Quarters > 1 > cash Flow > cash From Financing
-30202000
Quarters > 1 > cash Flow > net Change In Cash
4907000
Quarters > 1 > ratios > PE
0.6447390292553191
Quarters > 1 > ratios > PB
1.645603723916872
Quarters > 1 > ratios > ROE
4.09646697875329
Quarters > 1 > ratios > ROA
1.920966141346707
Quarters > 1 > ratios > FCF
25027000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.14349192152006146
Quarters > 1 > health Score
59
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
170528000
Quarters > 2 > income Statement > cost Of Revenue
85277000
Quarters > 2 > income Statement > gross Profit
85251000
Quarters > 2 > income Statement > operating Expenses
47958000
Quarters > 2 > income Statement > operating Income
37293000
Quarters > 2 > income Statement > interest Expense
6286000
Quarters > 2 > income Statement > pretax Income
30862000
Quarters > 2 > income Statement > net Income
25285000
Quarters > 2 > income Statement > eps
0.506814992984566
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
49890000
Quarters > 2 > income Statement > income Tax Expense
5577000
Quarters > 2 > income Statement > EBITDA
52355000
Quarters > 2 > income Statement > operating Margin
21.869135860386564
Quarters > 2 > income Statement > total Other Income Expense Net
-6431000
Quarters > 2 > balance Sheet > cash
182782000
Quarters > 2 > balance Sheet > short Term Investments
54101000
Quarters > 2 > balance Sheet > receivables
145394000
Quarters > 2 > balance Sheet > inventories
185476000
Quarters > 2 > balance Sheet > total Current Assets
587961000
Quarters > 2 > balance Sheet > property Plant Equipment
353759000
Quarters > 2 > balance Sheet > total Assets
1626276000
Quarters > 2 > balance Sheet > payables
52813000
Quarters > 2 > balance Sheet > short Term Debt
7970000
Quarters > 2 > balance Sheet > long Term Debt
603858000
Quarters > 2 > balance Sheet > total Liabilities
874993000
Quarters > 2 > balance Sheet > equity
751283000
Quarters > 2 > cash Flow > net Income
25285000
Quarters > 2 > cash Flow > depreciation
15207000
Quarters > 2 > cash Flow > change In Working Capital
-16714000
Quarters > 2 > cash Flow > cash From Operations
35077000
Quarters > 2 > cash Flow > capital Expenditures
10697000
Quarters > 2 > cash Flow > cash From Investing
10481000
Quarters > 2 > cash Flow > cash From Financing
-14503000
Quarters > 2 > cash Flow > net Change In Cash
31173000
Quarters > 2 > ratios > PE
0.506814992984566
Quarters > 2 > ratios > PB
1.7199257802985026
Quarters > 2 > ratios > ROE
3.365575954733436
Quarters > 2 > ratios > ROA
1.5547791395802435
Quarters > 2 > ratios > FCF
24380000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.14296772377556766
Quarters > 2 > health Score
58
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
186523000
Quarters > 3 > income Statement > cost Of Revenue
99875000
Quarters > 3 > income Statement > gross Profit
86648000
Quarters > 3 > income Statement > operating Expenses
41504000
Quarters > 3 > income Statement > operating Income
45144000
Quarters > 3 > income Statement > interest Expense
6425000
Quarters > 3 > income Statement > pretax Income
43962000
Quarters > 3 > income Statement > net Income
37964000
Quarters > 3 > income Statement > eps
0.7292635137730993
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
52058000
Quarters > 3 > income Statement > income Tax Expense
5998000
Quarters > 3 > income Statement > EBITDA
65051000
Quarters > 3 > income Statement > operating Margin
24.202913313639606
Quarters > 3 > income Statement > total Other Income Expense Net
-1182000
Quarters > 3 > balance Sheet > cash
151609000
Quarters > 3 > balance Sheet > short Term Investments
70036000
Quarters > 3 > balance Sheet > receivables
138036000
Quarters > 3 > balance Sheet > inventories
153741000
Quarters > 3 > balance Sheet > total Current Assets
534071000
Quarters > 3 > balance Sheet > property Plant Equipment
344627000
Quarters > 3 > balance Sheet > total Assets
1577470000
Quarters > 3 > balance Sheet > payables
30514000
Quarters > 3 > balance Sheet > short Term Debt
7038000
Quarters > 3 > balance Sheet > long Term Debt
601630000
Quarters > 3 > balance Sheet > total Liabilities
845172000
Quarters > 3 > balance Sheet > equity
732298000
Quarters > 3 > cash Flow > net Income
37964000
Quarters > 3 > cash Flow > depreciation
14664000
Quarters > 3 > cash Flow > change In Working Capital
-8590000
Quarters > 3 > cash Flow > cash From Operations
29024000
Quarters > 3 > cash Flow > capital Expenditures
12411000
Quarters > 3 > cash Flow > cash From Investing
-35678000
Quarters > 3 > cash Flow > cash From Financing
-33842000
Quarters > 3 > cash Flow > net Change In Cash
-40507000
Quarters > 3 > ratios > PE
0.7292635137730993
Quarters > 3 > ratios > PB
1.8411933393236086
Quarters > 3 > ratios > ROE
5.184228278651587
Quarters > 3 > ratios > ROA
2.4066384780693135
Quarters > 3 > ratios > FCF
16613000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
0.0890667638843467
Quarters > 3 > health Score
54
Valuation > metrics > PE
12.1062
Valuation > metrics > PB
1.5897530209360589
Valuation > final Score
100
Valuation > verdict
Fair
Profitability > metrics > ROE
2.2336774183581247
Profitability > metrics > ROA
2.7131843557946422
Profitability > metrics > Net Margin
0.09043994995829858
Profitability > final Score
26
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.1451310981968366
Risk > metrics > Interest Coverage
4.029280712921706
Risk > final Score
46
Risk > verdict
High
Liquidity > metrics > Current Ratio
12.97362548184216
Liquidity > metrics > Quick Ratio
9.201420166362345
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
51
Prev Profitabilities > 1
42
Prev Profitabilities > 2
62
Prev Risks > 0
57
Prev Risks > 1
54
Prev Risks > 2
58
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:25:13.461Z
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Technicals: Why AMPH stock is a must watch in 2025 - 2025 Key Highlights & AI Powered Market Trend Analysis moha.gov.vn
Read more →2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges - The Globe and Mail
12/11/2025
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges The Globe and Mail
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$32
Analyst Picks
Strong Buy
2
Buy
0
Hold
4
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 50.93% of the total shares of Amphastar P
1.
BlackRock Inc(12.1922%)
since
2025/06/30
2.
Vanguard Group Inc(5.779%)
since
2025/06/30
3.
TD Asset Management Inc(4.3767%)
since
2025/06/30
4.
Dimensional Fund Advisors, Inc.(3.499%)
since
2025/06/30
5.
State Street Corp(3.3901%)
since
2025/06/30
6.
Fuller & Thaler Asset Management Inc(2.7181%)
since
2025/06/30
7.
TD Global Investment Solutions – TD Epoch(2.6699%)
since
2025/06/30
8.
BTIM Corp(2.5303%)
since
2025/06/30
9.
Geode Capital Management, LLC(2.0932%)
since
2025/06/30
10.
Marshall Wace Asset Management Ltd(1.8253%)
since
2025/06/30
11.
Morgan Stanley - Brokerage Accounts(1.4651%)
since
2025/06/30
12.
Millennium Management LLC(1.3313%)
since
2025/06/30
13.
Renaissance Technologies Corp(1.2399%)
since
2025/06/30
14.
Qube Research & Technologies(1.0098%)
since
2025/06/30
15.
Northern Trust Corp(0.9058%)
since
2025/06/30
16.
Amvescap Plc.(0.8323%)
since
2025/06/30
17.
Hotchkis & Wiley Capital Management LLC(0.787%)
since
2025/06/30
18.
Systematic Financial Management LP(0.7728%)
since
2025/06/30
19.
Goldman Sachs Group Inc(0.7662%)
since
2025/06/30
20.
Charles Schwab Investment Management Inc(0.7459%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.